The results of the trial of Nymox's lead drug candidate for the treatment of benign prostatic hyperplasia (BPH), were reported during a recent review of safety data from its ongoing multi-center US phase II trial.
The biopharmaceutical company, which specializes in the research and development of therapeutics and diagnostics for the elderly, discovered there to be no overall sexual side effects from NX-1207, and a better side effect profile compared to existing drugs.
Previously Nymox reported that NX-1207 had been given a positive recommendation by the Independent Data Monitoring Committee for the trial evaluation of the efficacy and safety data at that point in time (January 2006).
NX-1207 has completed two earlier phase I and II trials where the drug produced on average over 23% prostate shrinkage in one month with minimal side effects.
BPH affects approximately 50% of men over 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.